Boston Scientific commences enrolment for MultiSENSE trial

Boston Scientific has begun enrolling participants for a new clinical trial that aims to establish better methods of monitoring and regulating heart failure.

The medical device company has enlisted its first patient for the MultiSENSE study, which will evaluate the physiologic sensors used in its Cognis cardiac resynchronisation therapy defibrillators (CRT-Ds).

It is hoped that thus study will allow for the development of an alert, which functions with Boston Scientific’s Latitude Patient Management System to provide physicians with notifications about patients’ conditions when they are outside a clinical setting.

This would allow action to be taken sooner should a patient’s heart failure worsen, meaning they could avoid hospitalisation.

Dr Kenneth Stein, chief medical officer for Boston Scientific’s cardiology, rhythm and vascular group said this makes the study a “significant step toward addressing the unmet needs of heart failure patients”.

This comes after Boston Scientific published a study last month which showed that women are more likely to benefit from CRT-D therapy than male patients.